Zetagen Therapeutics Secures USPTO Patents for Novel Intratumoral Breast Cancer Platform
核心洞察
Zetagen Therapeutics (搜索) has secured composition-of-matter patents from the USPTO (搜索) for its proprietary breast cancer platform, expanding its intellectual property portfolio to over 70 assets worldwide.
The patents protect three novel drug candidates delivered intratumorally: ZetaMet™ for bone metastases, ZetaMast (搜索)™ for liver metastases, and ZetaPrime (搜索)™ for primary HR+ breast cancer.
ZetaMet™ has received two FDA Breakthrough Designations and completed enrollment in a Phase 2a clinical trial, with full results anticipated in November 2025.
Zetagen Therapeutics (搜索), a clinical-stage biopharmaceutical company, has successfully secured foundational composition-of-matter patents from the USPTO (搜索) for its proprietary breast cancer platform. The patents protect three novel drug candidates designed for intratumoral administration: ZetaMet™, ZetaMast (搜索)™, and ZetaPrime (搜索)™, reinforcing the company's intellectual property estate that now surpasses 70 assets worldwide.
"Securing these allowances and composition-of-matter patents for our intratumorally administered breast cancer therapeutics represents a strategic leap forward in our mission to redefine oncologic care," said Joe C. Loy, CEO of Zetagen Therapeutics (搜索). "This latest patent protects the molecular uniqueness of our drug ZetaPrime (搜索)™ and affirms the disruptive potential in our pursuit to minimize off target side effects of conventional chemotherapeutics."
Intratumoral Delivery Platform
Zetagen's approach focuses on delivering proprietary and established molecules directly into tumors, reducing systemic toxicity and off-target side effects. This precision method protects healthy tissue while potentially improving survival outcomes by enhancing therapeutic efficacy at the site of disease. The company's growing patent portfolio underscores its commitment to advancing targeted oncology innovation.
"Receiving multiple composition-of-matter patents for our breast oncology candidates is a transformative milestone for our scientific and clinical mission," said Bryan S. Margulies, Ph.D., CSO of Zetagen Therapeutics (搜索). "By securing these patents, we validate the unique molecular design of our compounds and strengthen our pursuit of transformative therapies for underserved patient populations."
Lead Drug Candidate: ZetaMet™
ZetaMet™ (Zeta-BC-003) represents the company's most advanced program, targeting metastatic breast cancer in bone. The molecular pathway drug ceases lytic activity, inhibits pain, and regenerates new bone through locoregional administration via a 30-minute outpatient procedure. The treatment aims to minimize skeletal related events (SRE) while increasing survival rates.
The drug candidate has achieved significant regulatory recognition, receiving two FDA Breakthrough Designations and approval for treatment of eight Compassionate Use stage 4 cancer patients in the US and Canada. These patients had previously failed to respond to standard treatments including chemotherapy, surgery, and radiation.
ZetaMet™ has demonstrated cross-species efficacy at consistent concentrations, with findings published in several peer-reviewed journals, underscoring its translational promise from laboratory to clinic. Zetagen has successfully completed enrollment of a Phase 2a clinical trial for treating metastatic breast cancer to the spine at the University of British Columbia, with full study results anticipated in November 2025.
Pipeline Expansion
ZetaMast (搜索)™ (Zeta-MBC-005) is a proprietary drug-eluting hydrogel carrier designed for locoregional administration and controlled release of small molecules in treating multifocal, unresectable liver metastases from breast cancer. The company has completed preclinical studies, drug elution refinement, toxicity testing, and dose optimization studies, with results published in the peer-reviewed journal PLOS-One. Zetagen plans to file an IND with the FDA this fall and conduct a Phase 1b dose escalation study in early 2026 upon approval.
ZetaPrime (搜索)™ (Zeta-PBC-007) serves as a neo-adjuvant treatment for primary HR+ breast cancer, engineered for locoregional administration following diagnosis. The treatment utilizes a proprietary hydrogel-like lipid carrier formulation that enables controlled release of two small molecules, including a novel molecular entity and the ability to deliver CDK4 (搜索) or CDK4/6 (搜索) protein inhibitors. Designed for solubility within adipose tissue, the approach targets primary breast cancer while aiming to reduce the necessity for lumpectomies and mastectomies, postpone radiation exposure, and enhance patient survival.
Strategic Positioning
Founded in 2015, Zetagen Therapeutics (搜索) has positioned itself as a developer of proprietary carriers delivering tumoricidal therapies intratumorally via singular injection for primary and metastatic breast cancer. The company has enlisted Foley & Lardner LLP (搜索) as its intellectual property counsel, maintaining a collaborative relationship with the prominent law firm's specialized Life Sciences intellectual property expertise.
The newly secured patents strengthen Zetagen's appeal to investors, partners, and future acquirers by demonstrating defensible innovation in the competitive oncology landscape. The company plans to attend the San Antonio Breast Cancer Symposium (SABCS) in December to present its platform developments.